CTSO
—
—
Loading…
—
—
MASTER
—
—
ESEN VERDICT
Analyzing…
Horizon6–12M
Confidence—
Data coverage—
Live Market Snapshot — CTSO
Price
$0.354
Change
−4.32%
52W Range
$0.35–$1.22
52W Return
−61.10%
Market Cap
$23.3M
Beta
1.34
ESEN Master Institutional Assessment
| Metric | Grade | Score | Evidence | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | D+ | 42 | Severe earnings deterioration, massive YTD drawdown, micro-cap illiquidity, unproven turnaround path. | Speculative |
| Quality & Value Composite | D | 35 | EPS −$0.191 (deeply unprofitable), no P/E valuation anchor, weak balance signals, no dividend cushion. | 6–12M |
| Growth Sustainability & Moat | C− | 48 | Revenue +7.72% YoY shows modest top-line resilience; flagged hyper-growth but large EPS gap signals margin collapse or operational stress in healthcare biotech. | 6–12M |
| Valuation & Safety (Pre-Penalty) | C | 52 | Market cap $23.3M on negative earnings yields extreme leverage to binary outcomes; no forward P/E or target consensus available. | 3–6M |
| Institutional & Smart Money Flow | D | 38 | Micro-cap liquidity constraint (avg volume ~54k shares), 61% YTD loss suggests weak institutional conviction and momentum vacuum. | 1–3M |
| Penalty Overlay (Risk Adjustment) | −18 | −18 | Micro-cap liquidity penalty (−8), extreme drawdown flag (−6), missing earnings/guidance (−3), unprofitability haircut (−1). | Immediate |
| CONFIDENCE SCORE | C+ | 58 | Live price/volume data solid; earnings and full profile gaps limit conviction. Assessment based on disclosed metrics. | As-of |
| Volatility & Drawdown Risk | F | 18 | Beta 1.34 above market; 61% YTD loss, current price near 52W low ($0.354 vs $0.35 floor) signals acute distress and flash-crash vulnerability. | 1–3M |
| Crowding Risk Flag | Low | 72 | Sub-$25M market cap; minimal retail/institutional coverage; escape from crowded-trade risk offset by illiquidity premium. | Ongoing |
Peer & Sector Context
Cytosorbents Corp (NASDAQ: CTSO) is a micro-cap healthcare technology company in the medical devices / critical care segment. At $23.3M market cap and $0.354/share, it trades near the extreme bottom of its 52-week range and faces severe valuation compression. Peers in the critical care device space (e.g., Baxter, Fresenius, Edwards Lifesciences) trade at 15–22× P/E with strong profitability; CTSO's negative earnings and absence of analyst target consensus suggest institutional abandonment. Revenue growth of +7.72% YoY demonstrates modest market traction, but the massive gap between top-line growth and negative earnings reveals operational/margin deterioration—likely driven by R&D spend, regulatory costs, or manufacturing overhead in a biotech-device hybrid model. The "hyper-growth" flag in the dataset conflicts sharply with unprofitability, indicating early-stage commercialization stress typical of pre-inflection biotech plays.
Two-Horizon Forward Analysis
1–3 Month Outlook: Acute Distress Zone
Stock trades in extreme micro-cap distress territory. Price at $0.354 is 3 basis points above the 52-week low; any further deterioration risks delisting or reverse split. Beta 1.34 means volatility will amplify downside in a risk-off market. Absent a major clinical win, partnership announcement, or capital injection, the stock faces headwinds from:
- Illiquid order book with spread risk on any exit.
- Potential equity raise at depressed valuation (dilution risk).
- Negative earnings pressure if operating losses continue.
6–12 Month Outlook: Turnaround or Terminal
Medium-term trajectory hinges on two scenarios:
- Inflection Path: Revenue growth accelerates to double-digits, operating losses narrow, path to profitability emerges. This would require successful clinical evidence, reimbursement approval, or large partnership. Market would likely re-rate to $1.50–$2.50 on margin recovery.
- Deterioration Path: Continued revenue stagnation, cash burn accelerates, dilutive financing required. Stock could fall to $0.10–$0.20 or below, approaching delisting risk.
Critical Risk Alerts
🔴 Micro-Cap Liquidity Trap: Average volume ~54k shares/day; ask-bid spreads likely 5–15%. Position sizes >100k shares risk severe slippage. Institutional exit would trigger cascade sell-off.
🔴 Earnings Cliff: EPS −$0.191 signals sustained operating losses. No forward earnings guidance or analyst consensus available. Next earnings release will be binary event.
⚠️ Valuation Opacity: No forward P/E, no target price, no dividend cushion. Stock price driven by sentiment and catalysts, not fundamental anchors. Downside protected only by tech/biotech recovery narrative.
⚠️ Data Gaps: Earnings date, full balance sheet, cash position, and debt levels not disclosed in live feed. Coverage constraints limit conviction scoring.
FINAL INSTITUTIONAL VERDICT
CTSO is a high-risk, illiquid micro-cap in severe distress: Negative earnings, 61% YTD loss, near-delisting valuation, and micro-cap illiquidity create a speculative, binary-outcome profile unsuitable for mainstream institutional portfolios. Revenue growth hints at operational traction, but the absence of profitability and analyst coverage signals either early-stage commercialization risk or fundamental competitive weakness. Entry is only warranted for specialized biotech/turnaround funds with deep due diligence on clinical pipeline, cash runway, and near-term catalyst visibility. Base case: continued pressure to $0.10–$0.20 unless major catalyst materializes in next 6 months.
ESEN Master Score: 42/100 (D+) | Confidence: 58/100 (C+) | Horizon: Speculative | As-of: 2026-07-30 07:15 UTC
AI STOCK INSIGHT
CTSO Stock Analysis & Forecast
Is CTSO a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
CTSO Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, CTSO shows balanced risk-reward characteristics.
Should You Buy CTSO Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in CTSO.